Key result
Tenecteplase shows similar discharge independence and sICH to alteplase but achieves faster door-to-needle times.
Why the study?
Tenecteplase is at least non-inferior to alteplase for acute ischaemic stroke, but real-world data in routine UK clinical practice are limited.
Does tenecteplase improve process times, safety, and effectiveness compared to alteplase in patients with acute ischaemic stroke in routine practice?
Observational (n=12,919)
Yes
Does tenecteplase improve process times, safety, and effectiveness compared to alteplase in patients with acute ischaemic stroke in routine practice?
Real-world registry data demonstrates that tenecteplase is associated with faster treatment times and similar safety and effectiveness outcomes compared to alteplase in acute ischaemic stroke, supporting its use as a first-line thrombolytic agent.
Answers are grounded in this paper and cite their sources.
May enable faster thrombolysis with tenecteplase in routine UK practice; leaves open long-term outcomes versus alteplase.
Background and aims Tenecteplase (TNK) has been shown to be at least non inferior to Alteplase (rtPA) in the emergency treatment in acute ischaemic stroke but real world data is limited in the UK. This study aims to explore the safety and effectiveness of TNK in routine practice over one year. Methods Data from the National Stroke Registry for England, Wales, And Northern Ireland (The Sentinel Stroke National Audit Programme: SSNAP) were analysed for patients with ischaemic stroke treated with TNK and rtPA between October 2024 and September 2025. Results Of 12919 patients who underwent thrombolysis, 8284 (64.1%) received TNK and 4635 (35.9%) received rtPA. There were no differences in NIHSS on arrival (TNK 8, IQR: 5-15 vs rtPA 9, IQR 5-15, P>0.05). Higher rates of patients treated with TNK were thrombolysed within an hour of arrival (60.4% vs 52.8%, P<0.05) with faster door to needle times (53, IQR: 38-76 minutes vs 59, IQR: 42-86 minutes, P<0.05). There were higher rates of patients receiving rtPA who underwent thrombectomy (5.8% vs 6.9%, P<0.05). There were no differences in symptomatic intracranial haemorrhage (TNK: 3.3% vs rtPA: 3.4%, P>0.05). There were no differences in patients independent at discharge (modifed Rankin Score 0-2; TNK 49% vs rtPA 48%, P>0.05) nor inpatient mortality (TNK 10.8% vs rTPA 10.4%, P> 0.05). Conclusions Real world data revealed faster process times with TNK as well as similar effectiveness and safety outcomes supporting the transition of TNK over rtPA as the first line thrombolytic agent. Conflict of interest Kaili Stanley: nothing to disclose; Kevin Vasquez: nothing to disclose; Ajay Bhalla: nothing to disclose; Martin James: I have received speaker fees from Boehringer Ingelheim, the manufacturer of alteplase and tenecteplase.
No takes yet. Share an insight, caveat, or question.
Stanley et al. (2026) conducted an observational in acute ischaemic stroke (n=12,919). Tenecteplase (TNK) vs. Alteplase (rtPA) was evaluated on Independent at discharge (modified Rankin Score 0-2) (p=>0.05). Tenecteplase demonstrated similar rates of independence at discharge and symptomatic intracranial hemorrhage compared to alteplase, but with faster door-to-needle times.
Synapse has enriched 10 related papers. Consider them for comparative context: